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Abstract
Clinically used somatostatin (SRIF) analogs, octreotide and lanreotide, act primarily by binding to SRIF receptor subtype 2
(sst2). In contrast, the recently described multiligand SOM230 binds with high affinity to sst1e3 and sst5 and KE 108 is characterised
as a high affinity ligand for all five SRIF receptors. In tumoural mouse corticotrophs (AtT-20 cells) and in mouse hippocampus,
binding and functional features of KE 108 were examined and compared to SRIF-14, octreotide and SOM230. In AtT-20 cells, KE
108 bound with high affinity at [125I]LTT-SRIF-28-labelled sites similarly to SRIF-14, octreotide and SOM230. At the functional
level, all four ligands increased guanosine-5#-O-(3-[35S]thio)-triphosphate binding and decreased cAMP accumulation or
intracellular Ca2C concentration through Gi/o proteins. In hippocampal slices, KE 108, octreotide and SOM230 also bound with
high affinity at [125I]LTT-SRIF-28-labelled sites similarly to SRIF-14, but KE 108, octreotide or SOM230 did not influence
spontaneous epileptiform activity which was, in contrast, inhibited by SRIF-14. In conclusion, this study demonstrates that KE 108
has high affinity for native mouse SRIF receptors. Functionally, KE 108 mediates SRIF action at sst2/5 in corticotrophs whereas it
does not mimic the SRIF-induced inhibition of hippocampal excitation suggesting that the high potency and efficacy of a synthetic
ligand to all known SRIF receptors may not reproduce entirely the effects of the natural SRIF.
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1. Introduction
Somatostatin (SRIF: somatotropin-release inhibiting
factor) is a cyclic peptide that exists in two biologically
active forms, SRIF-14 and SRIF-28, which have been
linked to a number of pathologies, e.g. acromegaly, gas-
trointestinal disorders, tumours in addition to various
psychiatric or neurological diseases, e.g. epilepsy,
depression, schizophrenia and dementias. SRIFs are
predominantly produced by normal endocrine, gastro-
intestinal and immune cells, as well as by certain
tumours (Weckbecker et al., 2003). SRIFs are also
present in numerous neuronal cells throughout the
brain, including the hypothalamus and the hippocampal
formation (Binaschi et al., 2003; Olias et al., 2004).
SRIF actions are mediated by five receptors (sst1e5) that
are coupled to G proteins, and trigger multiple trans-
membrane signalling systems (Lahlou et al., 2004).
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